TOPIGEN Pharmaceuticals Reports Phase 2 Results Of TPI ASM8 In Asthma Patients
TOPIGEN Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focused on innovative respiratory therapeutics, today announced results of a Phase 2 14-day study of inhalable TPI ASM8 in patients with asthma.
More: continued here
Filed under: Respiratory on January 16th, 2009